



Fall Group Meeting  
**Chicago Specials**

SEPTEMBER 18-20, 2025

Lymphoma Committee

# Lymphoma Committee

## Leadership

Chair: ..... Jonathan W. Friedberg, MD  
 Vice-Chair: ..... Sonali M. Smith, MD  
 Executive Officer: ..... Susan M. O'Brien, MD  
 Statisticians: ..... Michael LeBlanc, PhD  
 ..... Hongli Li, MS  
 ..... Gabby Lopez, MS  
 ..... Matt Chansky, BS

## Scientific Leadership

Translational Medicine: ..... Alexey Danilov, MD, PhD  
 Radiation Oncology: ..... Nicholas Burden Figura, MD  
 Imaging: ..... Lawrence H. Schwartz, MD  
 Immunotherapeutics: ..... Sweetha Thiruvengadam, MD  
 Pathology: ..... Joo Y. Song, MD  
 Early Therapeutics: ..... Nasheed Mohammad Hossain, MD

## Designates

Cancer Control: ..... TBD  
 Veterans Affairs: ..... Helen Ma, MD  
 Data Coordinators: ..... Alex Rangel, BS  
 ..... Gabi Herbert, MS, BS  
 ..... Laura Wells, BA  
 ..... Daria Chugina, MD, CCRPS  
 Oncology Research Professionals:  
   CRA: ..... Erin M. Cebula, MPH  
   ..... Jacob Kedroske, BA  
   Nurse: ..... TBD  
 Patient Advocate: ..... Tricia Hernandez, MS  
 Pharmaceutical Science: ..... Dawud Nael Dawud Ellayan, PharmD  
 ..... Martina Fraga, PharmD  
 Protocol Project Manager: ..... Erin Rogers  
 Clinical Trials Program Manager: ..... Laura Gildner, MS

## Time/Location

Thursday, September 18, 2025 5:00 p.m. - 7:00 p.m.  
 Room: Regency C (Ballroom Level, West Tower)

## Agenda

1. **Welcome & Introductions** - Jonathan Friedberg, MD & Sonali Smith, MD
2. **Mini Symposium: Improving CAR-T Therapy**
  - a. Radiation bridging - Nicholas Figura, MD
  - b. Novel targeted approaches - Justin Kline, MD
  - c. Bispecific antibodies and S2114 rationale - Brian Hess, MD
  - d. Discussion and Q&A - Sonali Smith, MD

## 3. S1826 Update - Alex Herrera, MD

## 4. New study

S2506: Marginal zone lymphoma - Dr. Hu

## 5. SWOG Trial Updates

- |                                |   |
|--------------------------------|---|
| a. S2308                       | Nilanjan Ghosh, MD, PhD                       |
| b. S2207                       | Jennifer Amengual, MD /<br>Patrick Reagan, MD |
| c. S1925 CLL                   | Deborah Stephens, DO                          |
| d. S1918 phase 2 result timing | Elizabeth Brem, MD /<br>Sonali Smith, MD      |

## 6. Open Studies From Other Groups

- |                       |                       |
|-----------------------|-----------------------|
| a. EA4232 T-cell ASCT | Marc Hoffmann, MD     |
| b. AO51902 T-cell     | Jennifer Amengual, MD |
| c. AO52101 older MCL  | Tycel Phillips, MD    |
| d. AHOD2131 HL        | Boyu Hu, MD           |

## Developing Studies

**S2506**, "MOZART MZL: A Randomized 3-Arm Phase II Study Evaluating Mosunetuzumab Alone and In Combination with Either Zanubrutinib or Polatuzumab Vedotin for The Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma." Drs. B. Hu, B. Hu, and S. Smith.

## Active Studies

**S1918**, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. E. Brem and S. Smith. Activated: 3/19/21.

**S2114**, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. B. Hess and N. Hossain. Activated: 2/23/23.

**S2207**, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. J. Amengual, P. Reagan, and S. Smith. Activated: 6/30/23

# Lymphoma Committee

**S2308**, “Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma.” Drs. N. Ghosh and J. Friedberg. Activated: 8/1/24

**CTSU/EA4151**, “A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission.” Dr. Fenske. SWOG Champion: Dr. B. Till. Activated: 8/29/17.

**CTSU/ANHL1931**, “A Randomized Phase 3 trial of Nivolumab in Combination with Chemo immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B cell Lymphoma.” Dr. Roth. SWOG Champion: Dr. M. Kamdar. Activated 6/7/21.

**CTSU/A051902**, “A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas.” Dr. Mehta-Shah. SWOG Champion: Dr. J. Amengual. Activated 7/30/21.

**CTSU/A052101**, “A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON).” Dr. Beaven. SWOG Champion: Dr. T. Phillips. Activated 9/8/23.

**CTSU/AHOS2131**, “A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.” Dr. Henderson. SWOG Champion: Dr. B. Hu. Activated 4/28/23.

## Closed Studies

**S1608**, “Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma.” Dr. P. Barr. Activated: 8/10/17. Closed: 7/15/24

**CTSU/A051701**, “Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas.” Dr. Abramson. SWOG Champion: Dr. S. Smith. Activated: 8/7/19. Closed: 12/14/23.

**CTSU/EA4181**, “A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients  $\leq$  70 years Old with Untreated Mantle Cell Lymphoma.” Dr. Wagner-Johnson. SWOG Champion: Dr. S. Spurgeon. Activated: 10/3/19. Closed: 4/7/23

## Open Leukemia Studies

**S1905**, “A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL).” Drs. Advani, N. Papadantonakis, and C. Yueng. Activated: 8/17/20.

**S1925**, “A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” Dr. D. Stephens. Activated: 12/14/20.

## Developing Leukemia Studies

**S2504**, “A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT).” Drs. M. Shadman, D. Stephens, and A. Danilov.

## Closed Cancer Care Delivery Study

**S1912CD**, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Dr. V. Shankaran. Activated 7/26/21. Closed 12/16/24.

## Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

## Published/Accepted Manuscripts

**S0016** Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on SWOG S0016. Danilov A, Li H, Shadman M, Rimsza L, Zebari A, Smith S, LeBlanc M, Friedberg J, Carlson C, Song J. *Haematologica*, Jul 3. doi: 10.3324/haematol.2025.288057. Online ahead of print. 2025. <https://pubmed.ncbi.nlm.nih.gov/40605713/>

**S1826** Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced stage classic Hodgkin lymphoma. Rutherford S, Li H, Herrera A, LeBlanc M, Ahmed S, Davison K, Parsons S, Unger J, Perry A, Casulo C, Bartlett N, Tuscano J, Hess B, Torka P, Kumar P, Jacobs R, Song J, Castellino S, Kahl B, Leonard J, Smith S, Friedberg J, Evens A.

# Lymphoma Committee

Journal of Clinical Oncology Jun 16:JCO2500204, 2025.

<https://pubmed.ncbi.nlm.nih.gov/40523203/>

**S2308** Ghosh N, Bellasea S, Li H, Olszewski A, Bryan L, Danilov A, Smith S, LeBlanc M, Friedberg JW. SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma. *JCO Oncology Advances* Apr;2(1):e2500037, 2025.  
<https://pubmed.ncbi.nlm.nih.gov/40264918/>

**A051301** Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201. Andreadis C, Bobek O, Hsi ED, Fenske TS, Stiff PJ, Hill BT, Geyer SM, Horwitz M, Khimani F, Little RF, Dinner SN, Friedberg JW, Kahl BS, Perales MA, Devine SM, Leonard JP, Bartlett NL. *Leukemia & Lymphoma* Jul 9:1-10, 2025.  
<https://pubmed.ncbi.nlm.nih.gov/40632607/>

## Submitted Manuscripts

**S0816** Advanced Stage classical Hodgkin Lymphoma Patients with a Positive Interim-PET (PET-2) Deauville Score 5 After 2 ABVD Cycles: Viviani S, Pavoni S, Barrington S, Guerra L, Schoder H, Johnson P, Kirkwood A, Stephens D, Friedberg J, Chauvie S, Knopp M, Luminari S, Molin D, Corradini P, Gallamini A, Rambaldi A, Tarella C. A Pooled Analysis of Three Multicenter Trials. Submitted, 2025.

**S1826** Castellino S, Li H, Herrera A, Punnett A, LeBlanc M, Parsons S, Hodgson D, Keller F, Drachtman R, Lamble A, Forlenza C, Doan A, Rutherford S, Evens A, Little R, Smith M, Hoppe B, Song J, Smith S, Friedberg J, Kelly K. Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL). Submitted, 2025.

## Lymphoma Committee

**Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study**

	S1608	S1918	S2114	S2207	S2308	A051902	A052101	AH02131
Banner University Medical Center - Tucson	2	-	1	-	1	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	1	2	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	4	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	3	-	5	-	-	-	-	4
Cancer Research for the Ozarks NCORP	1	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	2	-	3	-	-	-	-
Cedars-Sinai Medical Center	-	1	-	4	-	-	-	3
City of Hope Comprehensive Cancer Center	8	11	-	-	5	-	-	16
Columbia University Minority Underserved NCORP	-	6	5	1	-	3	-	1
Columbus NCI Community Oncology Research Program	1	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	7	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	4	-	4	-	-	-
Georgia Cares Minority Underserved NCORP	-	2	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	2	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	-	-	-	1	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	3	3	-	-	-	-	-	7
Loyola University Medical Center	-	-	2	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	2	3	20	-	4	-	-	1
Michigan Cancer Research Consortium NCORP	1	8	-	1	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-
Northwestern University LAPS	1	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	2	-	-	4	-	-	-
Oregon Health and Science University	-	-	4	-	3	-	-	4
Pacific Cancer Research Consortium NCORP	-	-	9	1	-	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	1	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	2	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	7	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	4	-	-	-
University of Arkansas for Medical Sciences	-	-	8	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	4	-	11	-	4	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-	-
University of Rochester LAPS	16	-	9	7	10	6	13	18
University of Texas Health Science Center at San Antonio	-	-	13	1	10	-	-	1
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	8	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	12	-	-	4	-	-	6
Upstate Carolina Consortium Community Oncology Research Program	1	1	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	4	-	1	-	1	-
Wisconsin NCI Community Oncology Research Program	-	2	-	-	1	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	1	-
ALLIANCE	17	42	36	5	34	-	-	-
ECOG-ACRIN	5	17	10	-	15	-	-	-
NRG	11	7	5	4	4	-	-	-
<b>Total</b>	<b>78</b>	<b>136</b>	<b>143</b>	<b>27</b>	<b>126</b>	<b>17</b>	<b>19</b>	<b>62</b>

## Lymphoma Committee

Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	ANHL1931	E4412	EA4151
Banner University Medical Center - Tucson	-	-	1
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	23
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Cedars-Sinai Medical Center	1	-	-
City of Hope Comprehensive Cancer Center	15	-	18
Columbia University Minority Underserved NCORP	3	1	-
Columbus NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	15
Froedtert and the Medical College of Wisconsin LAPS	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-
Gulf South Minority Underserved NCORP	-	-	-
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	11	-
Loyola University Medical Center	-	-	5
Medical University of South Carolina Minority Underserved NCORP	-	-	2
Michigan Cancer Research Consortium NCORP	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	2
Nevada Cancer Research Foundation NCORP	-	1	-
Northwestern University LAPS	1	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	-	-	7
Pacific Cancer Research Consortium NCORP	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	2	-	-
UC San Diego Moores Cancer Center	-	-	1
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	7	5
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-
University of Kentucky/Markey Cancer Center	-	-	3
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	10	-	11
University of Texas Health Science Center at San Antonio	-	-	14
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	20
Upstate Carolina Consortium Community Oncology Research Program	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
<b>Total</b>	<b>33</b>	<b>20</b>	<b>135</b>

